N/A N=8 Wake Therapy in the Treatment of Depression
Major Depressive Disorder · Bipolar Disorder
Primary: Structured Interview for the Hamilton Depression Scale With Atypical Depression Supplement(SIGH-ADS) — 16.6 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=65 Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation: A Department of Defense Funded Multicenter Pilot Study
Rotator Cuff Repair · Anterior Cruciate Ligament Reconstruction · Ankle Arthrodesis or Arthroplasty
Primary: Opioid Consumption During First Postoperative Week — 5.0; 47.5 mg
N/A N=30 Low-calorie Diet and Body Composition Prior to Roux-en-Y Gastric Bypass
Morbid Obesity · Liver Fat
Primary: Change in Intra-hepatocellular Lipid Content (IHCL) Following the Pre-operative Diet — 40.0; 67.4; 0.1 percentage of change in IHCL
Early Phase 1 N=18 Ketamine Infusion for Social Anxiety Disorder
Social Anxiety Disorder
Primary: Visual Analogue Scale for Anxiety Symptoms (VAS-anxiety) — 12.1; 19.6 units on a scale
Phase 2 N=36 Effect of Intralymphatic Immunotherapy
Allergy · Immune Tolerance · Injection Site Discomfort
Primary: Change in cSMS (Combined Symptom and Medication Score) — 2.6; 2.3; 4.5 score on a scale
Phase 2 N=43 A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)
Carcinomatous Edema
Primary: Change in Body Weight From Baseline at Final IMP Administration — -0.69; -0.34; -1.13; 0.70 Kg
Phase 4 N=26 Improving Driving in Young People With Autism Spectrum Disorders
Autism Spectrum Disorder
Primary: Driving Performance - Measured by Mean Off-Road Glance Duration — 0.85; 0.90 Seconds
Phase 2 N=61 Testing Doxazosin to Treat Stress Mechanisms in Alcoholism
Alcoholism
Primary: Startle Potentiation During Stress Reactivity Task — 22.25; 20.76; 26.22; 22.21 microvolts
Phase 2 N=97 The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients
Cancer-related Cognitive Difficulties
Primary: Memory Performance as Assessed by Computerized Cognitive Assessment - Mean Values by Arm — 75.2; 82.7; 83.6; 74.3 % correct — p=0.9168
N/A N=57 Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic Fatty Liver Disease
Primary: Change in ALT Index — 42.238; 33.524; 36.667; 36.238 U/L
N/A N=31 Effects of Transcranial Direct Current Stimulation (tDCS) on Neuropathic Symptoms Following Burn Injury
Burn Injury · Chronic Pain · Pruritus
Primary: Change in Pain Scale — 4.45; 4.19 units on a scale
Phase 2 N=60 Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
Acute Myeloid Leukemia
Primary: Proportion of Participants With Relapse Free Survival (RFS) up to 18 Months Post Transplant (Full Analysis Set) by Kaplan-Meier Analysis — 0.93; 0.93; 0.80; 0.93…
N/A N=385 Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix
Preterm Birth
Primary: Spontaneous Delivery Before 34 Completed Weeks — 51; 12 Participants
Phase 2 N=77 Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
Cancer · Melanoma
Primary: Objective Response Rate (ORR) — 61 Percentage of Participants
N/A N=24 Cognitive Behavioural Therapy Software for the Treatment of Depression in People With Multiple Sclerosis
Depression · Multiple Sclerosis
Primary: Change in Self-reported Symptoms of Depression, as Measured by Total BDI-II Score — -5.33; -1.17; -2.00; 0.25 units on a scale